Topiramate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Topiramate: From Epilepsy to Trigeminal Nerve Neoplasm
One-Sentence Summary
Topiramate is an antiseizure medication, originally used for epilepsy, including generalized tonic-clonic seizures, partial epilepsy and Lennox-Gastaut syndrome. The TxGNN model predicts it may be effective for trigeminal nerve neoplasm, but there are currently 0 clinical trials and 0 publications supporting this specific direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Epilepsy (generalized tonic-clonic seizures, partial epilepsy, Lennox-Gastaut syndrome), per the knowledge-graph indication data. The Singapore licence records contain no indication text. |
| Predicted New Indication | Trigeminal nerve neoplasm |
| TxGNN Prediction Score | 99.70% |
| Evidence Level | L5 (model prediction only) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 10 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Topiramate is a broad-spectrum antiseizure drug. It is generally understood to act on voltage-gated sodium channels, enhance GABA-A activity, antagonize AMPA/kainate glutamate receptors and inhibit carbonic anhydrase. Its efficacy in epilepsy is well established.
The link to a tumour of the trigeminal nerve is weak. These mechanisms control neuronal hyperexcitability and do not act against tumour growth. The high score is therefore probably a graph-based artefact. The model may be picking up network proximity between topiramate and trigeminal-related nodes, such as trigeminal neuralgia, rather than any anti-neoplastic activity.
No plausible mechanistic link between topiramate and tumour control has been established in the data compiled for this report.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Topiramate has 10 valid single-ingredient registrations and none cancelled. The five main authorizations are below.
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN09689P | TOPAMAX 50 Tablet 50 mg | Film-coated tablet |
| SIN09687P | TOPAMAX 100 Tablet 100 mg | Film-coated tablet |
| SIN09688P | TOPAMAX 25 Tablet 25 mg | Film-coated tablet |
| SIN16662P | TROKENDI XR Extended-Release Capsule 25 mg | Extended-release capsule |
| SIN14131P | Topiron film-coated tablets 50 mg | Film-coated tablet |
The other five registrations are further strengths of Trokendi XR (50, 100 and 200 mg) and Topiron (25 and 100 mg). All forms are oral.
Safety Considerations
- Contraindications flagged in the knowledge graph (these are graph-derived associations, not label text): kidney disease, nephrolithiasis (including SLC26A1-related susceptibility), acute urate nephropathy, pyoureter, liver disease, gallbladder disease, diarrheal disease, ocular hypertension, metabolic acidosis and acidosis disorders, anxiety disorder, neurotic disorder, dysthymic disorder, amnestic disorder and retrograde amnesia.
- Drug Interactions (100 interactions recorded; the first 20 retrieved are summarised here):
- Major: metformin, and anticholinergic agents including hyoscyamine, atropine, scopolamine, glycopyrronium, clidinium, dicyclomine, mepenzolate, methscopolamine, propantheline and trospium.
- Moderate: pioglitazone, glyburide, morphine, dronabinol, nabilone, phentermine, metoclopramide, phenylbutyric acid and glycerol phenylbutyrate.
Please refer to the package insert for the full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for trigeminal nerve neoplasm is supported only by a graph-based score. There are no trials or literature, and no mechanistic basis for anti-tumour activity. Topiramate is well established and widely registered in Singapore, but that does not support this indication.
Other predictions for topiramate have more support. Trigeminal neuralgia (score 98.92%) is rated L2 with a recommendation of Proceed with Guardrails. Its evidence is a small randomized, placebo-controlled crossover pilot study and a meta-analysis against carbamazepine. The predicted seizure-related indications, such as audiogenic seizures and thinking seizures, are rated L3-L4. These may be better candidates for further evaluation.
To proceed, the following is needed:
- Mechanism of action (MOA) data
- Evidence of anti-neoplastic activity of topiramate, for example preclinical studies in trigeminal nerve tumour models
- Confirmation of whether the prediction reflects trigeminal neuralgia rather than a true neoplasm
- Package insert warnings and contraindications from the HSA website, to complete safety screening
- Route and formulation compatibility assessment for the proposed use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.